The investment from BGF will support the rollout of the metra liver preservation system in the United States.
"This investment is key for 2 reasons. First, the funding will be critical in allowing us to execute our commercial plans in the US. Secondly, having BGF at the board table will ensure we leverage its impressive track record of successfully guiding growing businesses to achieve their full potential. Ultimately this is great news for all our stakeholders including current investors, employees and patients requiring a lifesaving organ transplant."
The funding round was led by Equity Gap investors and the Scottish Investment Bank to accelerate customer growth and expand the team.
"Diverting an aircraft is an expensive and technically complex business. Although many carriers have voice support to doctors on the ground, it is often difficult for them to ‘review and recommend’ because of limited data."
— Anne Roberts, co-founder & chief executive officer
Playfair Capital has backed the health technology firm in its latest funding round.
"It is fantastic to be working with the Playfair Capital team who share our vision of making cutting edge research accessible to all healthcare providers and their patients"
The record European medtech financing was backed by new US investors and existing partners including LGT and Cambridge Innovation Capital.
"We are pleased to welcome new US investors whose calibre and scale are reflective of the scale of CMR's mission to transform surgery. I would also like to thank our existing investors for their long-term commitment in supporting this company to achieve its global mission. The significant capital injection in a UK scale-up reconfirms my belief that the Cambridge eco system has fostered a unique pool of diverse talents and competencies that will help drive our innovation in the years ahead. With new and existing investors onboard, CMR is well-placed to make surgical robotics accessible for all."
The funding round was led by UCL Technology Fund, Parkwalk, and Innovate UK to support sensor development and clinical trials.
"Coronary heart disease is endemic worldwide but far too often the decision to implant a stent is based on sub-optimal information. Our technology addresses the ‘grey zone’ of patients where the requirement for a stent is currently difficult to determine. By using advanced optical sensing technology, we hope to significantly improve the accuracy of current treatments, saving healthcare costs and preventing unnecessary operations for patients that could be treated with medicines."
